Monoclonal antibodies are immunoglobulins or a fragment of an immunoglobulin, with defined specificity, produced by a single clone of cells. They can be obtained from immortalized B-lymphocytes that are cloned and expanded as continuous cell lines (murine and human monoclonal antibodies) or from rDNA-engineered mammalian or bacterial cell lines (engineered monoclonal antibodies).
MONOCLONAL ANTIBODIES
A) Preparation
Monoclonal antibodies are immunoglobulins or a fragment of an immunoglobulin, with
defined specificity, produced by a single clone
of cells. They
can be obtained from immortalized B-lymphocytes that are cloned and
expanded as continuous cell lines (murine and human
monoclonal antibodies)
or from rDNA-engineered mammalian or bacterial cell lines (engineered monoclonal antibodies). Production of monoclonal antibodies is based on a seed lot system
using a master
cell bank and a working cell bank derived
from the cloned
cells. Two approaches
are currently in use: single harvest (produc tion at finite passage level) and multiple
harvest (continuous-culture production). In the first method, the cells are cultivated up to a defined maximum
number of passages or population doublings (in accordance with the stability of the cell line).
In the second method, cells
are continuously cultivated for a defined
period (in accordance with the stability of the system
and production consistency).
In this case,
monitoring is necessary throughout the life of the culture; the required frequency and type of monitoring will depend on the nature
of the production system. Bulk harvests
can be made by pooling
individual harvests before purification. The purification process to remove
unwanted host cell
derived proteins, nucleic
acids and carbohydrates
is also designed to remove and/or
inactivate non-enveloped and enveloped viruses and other impurities.
The quality
of therapeutic monoclonal antibodies is controlled by rigorous
characterization of the products by chemical and biological methods. The final product
should be tested for bioburden and bacterial endotoxins, purity, integrity and potency by suitable analytical methods, comparing with a reference preparation. The identity test can be done by suitable methods
comparing the product
with the reference preparation. Molecular
size distribution can be determined by size-exclusion chromatography. Depending on the nature
of the monoclonal antibody, its microheterogeneity and
isoforms, a number of
different tests can be used to demonstrate
molecular identity and structural integrity. These tests may include
peptide mapping, isoelectric focusing, ion-exchange
chromatography, hydrophobic interaction chromatography, oligosaccharide mapping, monosaccharide content
and mass spectrometry. The purity can be
examined by SDS–polyacrylamide gel electrophoresis under reducing and non-reducing conditions or capillary
electrophoresis. For monoclonal antibodies with specific antimicrobial activity,
an appropriate assay is performed to determine the
level of this.
Monoclonal antibodies have been developed for postexposure prophylaxis of
anthrax (anti-Protective Antigen), botulism (anti-toxins
A–G) and plague (anti-V antigen). Monoclonal antibodies
directed against the core region of Gram-negative bacterial endotoxins and intended for treatment of sepsis,
have met with little success.
Related Topics
TH 2019 - 2025 pharmacy180.com; Developed by Therithal info.